WO2015166379A3 - Nouvelles formes polymorphes de la vortioxétine et de ses sels pharmaceutiquement acceptables - Google Patents
Nouvelles formes polymorphes de la vortioxétine et de ses sels pharmaceutiquement acceptables Download PDFInfo
- Publication number
- WO2015166379A3 WO2015166379A3 PCT/IB2015/052904 IB2015052904W WO2015166379A3 WO 2015166379 A3 WO2015166379 A3 WO 2015166379A3 IB 2015052904 W IB2015052904 W IB 2015052904W WO 2015166379 A3 WO2015166379 A3 WO 2015166379A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vortioxetine
- pharmaceutically acceptable
- acceptable salts
- polymorphic forms
- novel polymorphic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15785569.3A EP3137083A2 (fr) | 2014-04-28 | 2015-04-21 | Nouvelles formes polymorphes de la vortioxétine et de ses sels pharmaceutiquement acceptables |
CA2940097A CA2940097A1 (fr) | 2014-04-28 | 2015-04-21 | Nouvelles formes polymorphes de la vortioxetine et de ses sels pharmaceutiquement acceptables |
AU2015254949A AU2015254949A1 (en) | 2014-04-28 | 2015-04-21 | Novel polymorphic forms of Vortioxetine and its pharmaceutically acceptable salts |
US15/304,929 US10071092B2 (en) | 2014-04-28 | 2015-04-21 | Polymorphic forms of vortioxetine and its pharmaceutically acceptable salts |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1476/MUM/2014 | 2014-04-28 | ||
IN1476MU2014 | 2014-04-28 | ||
IN3288/MUM/2014 | 2014-10-14 | ||
IN3288MU2014 | 2014-10-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015166379A2 WO2015166379A2 (fr) | 2015-11-05 |
WO2015166379A3 true WO2015166379A3 (fr) | 2016-03-03 |
Family
ID=54359441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/052904 WO2015166379A2 (fr) | 2014-04-28 | 2015-04-21 | Nouvelles formes polymorphes de la vortioxétine et de ses sels pharmaceutiquement acceptables |
Country Status (5)
Country | Link |
---|---|
US (1) | US10071092B2 (fr) |
EP (1) | EP3137083A2 (fr) |
AU (1) | AU2015254949A1 (fr) |
CA (1) | CA2940097A1 (fr) |
WO (1) | WO2015166379A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105209036B (zh) | 2013-04-09 | 2018-10-26 | 莱克斯特生物技术公司 | 氧杂双环庚烷和氧杂双环庚烯的配制品 |
US9687484B2 (en) | 2014-07-18 | 2017-06-27 | Dipharma Francis S.R.L. | Crystalline forms of an antidepressant compound |
EP3209297A1 (fr) * | 2014-10-24 | 2017-08-30 | Hexal Aktiengesellschaft | Bromhydrate de vortioxétine amorphe |
WO2016079751A2 (fr) * | 2014-11-17 | 2016-05-26 | Megafine Pharma (P) Ltd. | Procédé de préparation de vortioxétine et de polymorphes de cette substance |
CZ201531A3 (cs) * | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Polymerem stabilizované amorfní formy vortioxetinu |
CN105622546B (zh) * | 2016-01-07 | 2020-08-28 | 万全万特制药(厦门)有限公司 | 沃替西汀的一种制备方法 |
WO2017154016A1 (fr) * | 2016-03-07 | 2017-09-14 | Msn Laboratories Private Limited | Nouveaux polymorphes cristallins de bromhydrate de 1-[2-(2,4-diméthyl-phénylsulfanyl)- phényl]-pipérazine et leur procédé de préparation |
US10519121B2 (en) * | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
US11020390B2 (en) * | 2017-02-17 | 2021-06-01 | Unichem Laboratories Ltd | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide |
EP3412661A1 (fr) | 2017-06-08 | 2018-12-12 | Enantia, S.L. | Co-cristaux de bromhydrate vortioxetine et du résorcinol |
KR102026337B1 (ko) | 2017-07-07 | 2019-09-27 | 영진약품 주식회사 | 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법 |
CN109928941A (zh) * | 2017-12-19 | 2019-06-25 | 成都弘达药业有限公司 | 一种氢溴酸沃替西汀的结晶化合物及其制备方法 |
CN108912069A (zh) * | 2018-08-22 | 2018-11-30 | 梧州学院 | 一种沃替西汀与c2-c4二羧酸新盐型及其制备方法与应用 |
CN111320592A (zh) * | 2018-12-17 | 2020-06-23 | 天津理工大学 | 一种1-[2-(2,4-二甲基苯硫基)-苯基]哌嗪的制备方法 |
TR202001040A2 (tr) * | 2020-01-23 | 2021-07-26 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vorti̇okseti̇n hi̇drobromi̇di̇n kri̇stali̇n c formu |
CN115160258B (zh) * | 2022-06-24 | 2023-11-17 | 辰欣药业股份有限公司 | 一种氢溴酸沃替西汀γ晶型的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2885266A1 (fr) * | 2012-09-19 | 2014-03-27 | Sandoz Ag | Nouvelle forme cristalline de bromhydrate de vortioxetine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4590013B2 (ja) * | 2006-06-16 | 2010-12-01 | ハー・ルンドベック・アクチエゼルスカベット | 認識機能障害(cognitiveimpairment)を治療するための、組み合わされたセロトニン再取り込み、5−HT3および5−HT1A活性を有する化合物としての1−[2−(2,4−ジメチルフェニルスルファニル)−フェニル]ピペラジン |
AU2013273868A1 (en) * | 2012-06-13 | 2015-02-05 | Apotex Inc. | Forms of Vilazodone and processes for the preparation thereof |
-
2015
- 2015-04-21 AU AU2015254949A patent/AU2015254949A1/en not_active Abandoned
- 2015-04-21 CA CA2940097A patent/CA2940097A1/fr not_active Abandoned
- 2015-04-21 WO PCT/IB2015/052904 patent/WO2015166379A2/fr active Application Filing
- 2015-04-21 US US15/304,929 patent/US10071092B2/en active Active
- 2015-04-21 EP EP15785569.3A patent/EP3137083A2/fr not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2885266A1 (fr) * | 2012-09-19 | 2014-03-27 | Sandoz Ag | Nouvelle forme cristalline de bromhydrate de vortioxetine |
Also Published As
Publication number | Publication date |
---|---|
CA2940097A1 (fr) | 2015-11-05 |
WO2015166379A2 (fr) | 2015-11-05 |
AU2015254949A1 (en) | 2016-10-06 |
US20170189394A1 (en) | 2017-07-06 |
US10071092B2 (en) | 2018-09-11 |
EP3137083A2 (fr) | 2017-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015166379A3 (fr) | Nouvelles formes polymorphes de la vortioxétine et de ses sels pharmaceutiquement acceptables | |
WO2016079751A3 (fr) | Procédé de préparation de vortioxétine et de polymorphes de cette substance | |
IL273730A (en) | crystalline forms | |
EP3672912A4 (fr) | Molybdotungstate de métal de transition cristallin | |
WO2015110897A3 (fr) | Nouveau procédé de préparation de dolutégravir et de ses sels pharmaceutiquement acceptables | |
WO2016011390A8 (fr) | Agents d'inhibition de l'irak 4 | |
IL276644A (en) | crystalline forms | |
MA39749A (fr) | Dérivés de pipéridine-dione | |
IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitantane | |
WO2016038542A3 (fr) | Formes polymorphes de sofosbuvir | |
EP3480198A4 (fr) | Nouveau composé ou son sel pharmaceutiquement accepté | |
WO2015142903A3 (fr) | Procédé pour réguler la production de lactate à l'aide de dérivés de pipéridine-dione | |
WO2016125192A3 (fr) | Procédé de préparation de dolutégravir | |
WO2015171526A3 (fr) | Composés de pyrazolopyridine tricycliques | |
PH12016501252A1 (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
EP3340973A4 (fr) | Sels pharmaceutiquement acceptables d'acide bêta-guanidinopropionique ayant des propriétés améliorées et utilisations de ceux-ci | |
WO2016125191A3 (fr) | Procédés de préparation de bromhydrate de vortioxétine | |
WO2014125506A3 (fr) | Procédé de préparation d'ivacaftor et de ses intermédiaires | |
EP3102036A4 (fr) | Dérivé de carbonyle -naphto [2,3-b]furane 3-substitué dérivé ou sel pharmaceutiquement acceptable de celui-ci | |
IL273896A (en) | Crystal forms of 3-disubstituted 1, 2, 4-oxadiazole | |
WO2015068175A3 (fr) | Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci | |
WO2018069941A3 (fr) | Formes polymorphes de vénétoclax | |
WO2015111085A8 (fr) | Procédés de préparation d'eltrombopag et sels pharmaceutiquement acceptables, solvates et intermédiaires de celui-ci | |
WO2017098533A3 (fr) | Procédé de préparation de lisdexamphétamine | |
WO2016092442A8 (fr) | Procédés de préparation de formes cristallines d'acétate de palbociclib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15785569 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2940097 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2015785569 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015785569 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015254949 Country of ref document: AU Date of ref document: 20150421 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15785569 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15304929 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |